Compare American Airlines Group Inc (AAL) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Airlines Group Inc vs Crispr Therapeutics AG — how do they compare? American Airlines Group Inc trades at $14.99 (market cap $10.55B), while Crispr Therapeutics AG trades at $53.89 (market cap $5.23B). The key difference: American Airlines Group Inc is far larger — about 2× Crispr Therapeutics AG's market cap, and American Airlines Group Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| AAL | CRSP | |
|---|---|---|
Market Cap | $10.55B | $5.23B |
Sector | Industrials | Health |
52-Week High | $18.15 | $76.78 |
52-Week Low | $10.18 | $44.34 |
Enterprise Value | $38.51B | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American Airlines (AAL) trades at $15.06, up 0.37% today, with technical indicators showing a bearish bias despite recent earnings beats. The company reported mixed Q2 2026 results with revenue growth but faces margin pressure from fuel costs. Analyst consensus is a Buy with a $19.63 price target, though high debt and volatile profitability remain concerns.
AAL offers potential upside from its discounted valuation and premium revenue recovery, but investors face risks from fuel price volatility, high leverage, and competitive pressures. The stock's outlook hinges on sustained travel demand and cost management amid economic uncertainty.
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Airlines Group Inc
American Airlines is the world's largest airline by scheduled revenue passenger miles. The firm's major hubs are Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. After completing a major fleet renewal, the company has the youngest fleet of U.S. legacy carriers.
Read more on AAL →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
